Benitec Biopharma Ltd Stock Performance
| BNTC Stock | USD 6.72 0.14 2.04% |
Benitec Biopharma holds a performance score of 15 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.95, which signifies possible diversification benefits within a given portfolio. Benitec Biopharma returns are very sensitive to returns on the market. As the market goes up or down, Benitec Biopharma is expected to follow. Use Benitec Biopharma sortino ratio, skewness, period momentum indicator, as well as the relationship between the potential upside and rate of daily change , to analyze future returns on Benitec Biopharma.
Risk-Adjusted Performance
15 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Benitec Biopharma Ltd are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating basic indicators, Benitec Biopharma exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.16) | Five Day Return (0.88) | Year To Date Return 107.34 | Ten Year Return (99.89) | All Time Return (99.89) |
Last Split Factor 1:17 | Dividend Date 2019-11-18 | Last Split Date 2023-07-26 |
1 | Benitec Biopharma Price Target Increased by 66.67 percent to 10.20 - msnNOW | 02/26/2024 |
2 | Acquisition by Megan Boston of 200004 shares of Benitec Biopharma at 5.21 subject to Rule 16b-3 | 03/06/2024 |
3 | Benitec Biopharma Awards Stock Options to Top Executives - TipRanks.com - TipRanks | 03/08/2024 |
4 | Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b2a Study | 04/18/2024 |
5 | Benitec BioPharma PT Raised to 16 at JMP Securities | 04/22/2024 |
| Begin Period Cash Flow | 4.1 M | |
| Total Cashflows From Investing Activities | -1000.00 |
Benitec |
Benitec Biopharma Relative Risk vs. Return Landscape
If you would invest 307.00 in Benitec Biopharma Ltd on January 26, 2024 and sell it today you would earn a total of 365.00 from holding Benitec Biopharma Ltd or generate 118.89% return on investment over 90 days. Benitec Biopharma Ltd is currently generating 1.5367% in daily expected returns and assumes 7.7756% risk (volatility on return distribution) over the 90 days horizon. In different words, 68% of stocks are less volatile than Benitec, and 70% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Benitec Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Benitec Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Benitec Biopharma Ltd, and traders can use it to determine the average amount a Benitec Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1976
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | BNTC | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.78 actual daily | 68 68% of assets are less volatile |
Expected Return
| 1.54 actual daily | 30 70% of assets have higher returns |
Risk-Adjusted Return
| 0.2 actual daily | 15 85% of assets perform better |
Based on monthly moving average Benitec Biopharma is performing at about 15% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Benitec Biopharma by adding it to a well-diversified portfolio.
Benitec Biopharma Fundamentals Growth
Benitec Stock prices reflect investors' perceptions of the future prospects and financial health of Benitec Biopharma, and Benitec Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Benitec Stock performance.
| Return On Equity | -1.78 | ||||
| Return On Asset | -0.82 | ||||
| Operating Margin | (355.61) % | ||||
| Current Valuation | (2.17 M) | ||||
| Shares Outstanding | 2.59 M | ||||
| Price To Earning | (5.10) X | ||||
| Price To Book | 0.92 X | ||||
| Price To Sales | 233.74 X | ||||
| Revenue | 75 K | ||||
| Gross Profit | 75 K | ||||
| EBITDA | (18.73 M) | ||||
| Net Income | (19.56 M) | ||||
| Cash And Equivalents | 4.06 M | ||||
| Cash Per Share | 0.50 X | ||||
| Total Debt | 559 K | ||||
| Debt To Equity | 0.28 % | ||||
| Current Ratio | 1.90 X | ||||
| Book Value Per Share | 5.97 X | ||||
| Cash Flow From Operations | (18.01 M) | ||||
| Earnings Per Share | (236.13) X | ||||
| Market Capitalization | 58.39 M | ||||
| Total Asset | 4.46 M | ||||
| Retained Earnings | (167.89 M) | ||||
| Working Capital | (249 K) | ||||
| Current Asset | 19.38 M | ||||
| Current Liabilities | 1.03 M | ||||
About Benitec Biopharma Performance
To evaluate Benitec Biopharma Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Benitec Biopharma generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Benitec Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Benitec Biopharma market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Benitec's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 14.32 | 13.61 | |
| Return On Tangible Assets | (5.04) | (4.79) | |
| Return On Capital Employed | (45.15) | (42.89) | |
| Return On Assets | (5.04) | (4.79) | |
| Return On Equity | (111.37) | (105.80) |
Things to note about Benitec Biopharma performance evaluation
Checking the ongoing alerts about Benitec Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Benitec Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Benitec Biopharma is way too risky over 90 days horizon | |
| Benitec Biopharma appears to be risky and price may revert if volatility continues | |
| Benitec Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 75 K. Net Loss for the year was (19.56 M) with profit before overhead, payroll, taxes, and interest of 75 K. | |
| Benitec Biopharma Ltd currently holds about 4.06 M in cash with (18.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.5. | |
| Benitec Biopharma has a poor financial position based on the latest SEC disclosures | |
| Latest headline from streetinsider.com: Benitec BioPharma PT Raised to 16 at JMP Securities |
- Analyzing Benitec Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Benitec Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Benitec Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Benitec Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Benitec Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Benitec Biopharma's stock. These opinions can provide insight into Benitec Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Benitec Biopharma Ltd. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Complementary Tools for Benitec Stock analysis
When running Benitec Biopharma's price analysis, check to measure Benitec Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Benitec Biopharma is operating at the current time. Most of Benitec Biopharma's value examination focuses on studying past and present price action to predict the probability of Benitec Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Benitec Biopharma's price. Additionally, you may evaluate how the addition of Benitec Biopharma to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Stocks Directory Find actively traded stocks across global markets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |
Is Benitec Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Benitec Biopharma. If investors know Benitec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Benitec Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (236.13) | Revenue Per Share 0.03 | Quarterly Revenue Growth 0.125 | Return On Assets (0.82) | Return On Equity (1.78) |
The market value of Benitec Biopharma is measured differently than its book value, which is the value of Benitec that is recorded on the company's balance sheet. Investors also form their own opinion of Benitec Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Benitec Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Benitec Biopharma's market value can be influenced by many factors that don't directly affect Benitec Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Benitec Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Benitec Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Benitec Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.